Project Grant R44AI191921
Award Date 9/1/25
Completion Date 7/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $309,418 Project Grant to Oleolive, Inc. to develop an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The award, made on September 20, 2025, will support research to repurpose the FDA-approved drug pyrvinium as an inhalation treatment for IPF, a fatal lung disease affecting 40,000 U.S. patients annually. The project aims to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $308,669 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to Vishenary, LLC to develop a novel vaccine with broad efficacy against nontypeable Haemophilus influenzae (NTHI) strains following influenza A virus (IAV) infection. The project aims to create a vaccine candidate consisting of a conserved NTHI protein (Protein 0259) and the FDA-approved histone deacetylase inhibitor...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This $489,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support the establishment of a new in vitro lung alveolar epithelial cell organoid model derived from human bronchoalveolar lavage fluid (BALF). The goal is to develop a physiologically relevant model for studying the human innate immune response to Mycobacterium tuberculosis (MTB) infection and evaluate the effects...
- This federal Project Grant award of $596,115 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the long-term impact of persistent parainfluenza virus infection. The research aims to expand understanding of the biology, ecology, and evolution of common respiratory viruses and their potential to drive chronic lung diseases like asthma. The 5-year project will be conducted by...
- This federal Project Grant award, valued at $155,227.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease, which currently has no FDA-approved treatments. The strategy involves using a biofilm disruptor as an adjunct to antibiotics to more effectively...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Via Therapeutics, LLC, a pharmaceutical research and development company based in Austin, Texas. The grant supports the development of an inhaled, fixed-dose combination powder product containing both azithromycin and amikacin for the treatment of non-tuberculous mycobacterial (NTM) infections. The goal is to improve...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The grant aims to develop two innovative vaccine candidates to prevent pulmonary nontuberculous mycobacterial (NTM) infections, which have surpassed tuberculosis as a global health concern. The research involves screening 13 vaccine...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...